Hims & Hers Health (HIMS) Depreciation & Amortization (CF) (2020 - 2026)
Hims & Hers Health (HIMS) posted Depreciation & Amortization (CF) of $22.0 million for Q1 2026, up 21.34% sequentially from $18.1 million in Q4 2025, and up 165.26% YoY from $8.3 million in Q1 2025.
Hims & Hers Health (HIMS) Depreciation & Amortization (CF) (2020 - 2026) Analysis & Trends
Hims & Hers Health has reported Depreciation & Amortization (CF) for 7 years, with the latest figure at $22.0 million in Q1 2026.
- Quarterly Depreciation & Amortization (CF) rose 165.26% year-over-year to $22.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $56.1 million (up 172.06% YoY) and the FY2025 annual result came in at $54.5 million, up 218.95% from the prior year.
- Depreciation & Amortization (CF) advanced to $22.0 million in Q1 2026 per HIMS's latest filing, from $18.1 million in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $22.0 million in Q1 2026 and troughed at $900000.0 in Q3 2022.
- A 5-year average of $5.5 million and a median of $2.8 million in 2024 frame the typical range for Depreciation & Amortization (CF).
- The widest YoY moves for Depreciation & Amortization (CF): up 341.88% in 2022, down 41.79% in 2022.
- Over 5 years, Depreciation & Amortization (CF) stood at $2.0 million in 2022, then jumped by 32.24% to $2.7 million in 2023, then soared by 128.03% to $6.1 million in 2024, then jumped by 198.5% to $18.1 million in 2025, then rose by 21.34% to $22.0 million in 2026.
- According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $22.0 million, $18.1 million, and $8.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 241.00 Mn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 119.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 1.02 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 24.20 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | 672.30 Mn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 171.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Hims & Hers Health | 7.81 Bn | 6.97 Bn | 480.80 Mn | 10.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.70 Mn |
| Jun 30, 2026 | 10.70 Mn |
| Mar 31, 2026 | 21.95 Mn |
| Mar 31, 2026 | 21.95 Mn |
| Dec 31, 2025 | 18.09 Mn |
| Dec 31, 2025 | 18.09 Mn |
| Sep 30, 2025 | 8.50 Mn |
| Sep 30, 2025 | 8.50 Mn |
| Jun 30, 2025 | 7.60 Mn |
| Jun 30, 2025 | 7.60 Mn |
| Mar 31, 2025 | 8.28 Mn |
| Mar 31, 2025 | 8.28 Mn |
| Dec 31, 2024 | 6.06 Mn |
| Dec 31, 2024 | 6.06 Mn |
| Sep 30, 2024 | 3.50 Mn |
| Sep 30, 2024 | 3.50 Mn |
| Jun 30, 2024 | 2.80 Mn |
| Jun 30, 2024 | 2.80 Mn |
| Mar 31, 2024 | 3.00 Mn |
| Mar 31, 2024 | 3.00 Mn |